Cencora, Inc.COR
Cencora, Inc. Financial Overview 2021–2025
Updated Jul 10, 2026Driven by a massive 26.9% spike in sales of GLP-1 weight loss and diabetes medications, Cencora generated $7.7 billion from this drug class alone in FY2025. This explosive demand underscores the core investment thesis: despite carrying billions in ongoing opioid settlement liabilities, Cencora is effectively monetizing the biggest trends in modern pharmacy while executing an aggressive global acquisition strategy. This dual engine of organic volume and strategic buyouts helped overall revenue grow from $213.99 billion in FY2021 to a record $321.3 billion in FY2025.
Beneath the top-line expansion, gross profit rose 15.8% to $11.5 billion in FY2025, aided by higher specialty sales and antitrust litigation settlements. Cencora also deployed serious capital to deepen its specialty pipeline, completing the $5.7 billion acquisition of Retina Consultants of America. While this move required new debt that drove an 85.7% increase in net interest expense, equity investors remained bullish on the distributor's underlying cash flow generation. At the close of FY2025, the market valued the company at a $60.6 billion market cap, with shares trading at $312.53 and a 39.3x price-to-earnings multiple.
Recent Developments (Q1 and Q2 2026)
Cencora executed a significant strategic pivot in early 2026, acquiring OneOncology for $7.4 billion while divesting its MWI Animal Health unit in a transaction valuing the business at a $3.5 billion enterprise value. Top-line momentum continued for the six months ended March 31, 2026, with revenue growing 4.7% to $164.3 billion and gross profit jumping 18.6% to $6.7 billion. The company also announced a major leadership transition, appointing Eva C. Boratto to succeed retiring CFO James F. Cleary. Bulls argue this sharpened focus on human oncology and specialty products will accelerate long-term profitability. Conversely, bears warn that funding the OneOncology buyout drove a 61.4% surge in six-month net interest expense, adding pressure to the balance sheet. Trading at 31.8x earnings as of May 6, 2026, the stock reflects a more moderate valuation following recent portfolio realignments.
What to watch: margin impacts from integrating the OneOncology acquisition; execution of the CFO transition during the second half of 2026.
Rev
$321.33B
FY2025
NI
$1.55B
FY2025
EPS
$8.02
FY2025
OCF
$3.88B
FY2025
Year-over-year comparison from 10-K annual reports
Data from SEC Company Facts
Recent SEC Filings
Cencora, Inc. 8-K Report, Executive Changes (Jun 15, 2026)
Cencora, Inc. (COR) has filed an 8-K report announcing a significant leadership change within its Human Resources department. Silvana Battaglia, Executive Vice President and Chief Human Resources Officer, will retire effective July 12, 2026, after a period of advisory service through the end of 2026. Importantly, her retirement is not attributed to any disagreements concerning the Company's operations or policies, suggesting a smooth transition. The company has appointed Samantha L. Hammock to succeed Ms. Battaglia as the new Executive Vice President and Chief Human Resources Officer, effective July 13, 2026. Ms. Hammock brings extensive experience to Cencora, having most recently held the same role at Verizon Communications Inc. This appointment signals a continued focus on strategic human capital management by the company.
Cencora, Inc. 8-K Report, Executive Changes (May 29, 2026)
Cencora, Inc. (COR) announced a significant leadership transition with the appointment of Eva C. Boratto as Executive Vice President and Chief Financial Officer, effective June 29, 2026. Ms. Boratto brings extensive financial leadership experience, including previous CFO roles at Bath & Body Works and significant tenures at CVS Health and Merck & Co. She also serves on the boards of Mars, Inc. and United Parcel Service, Inc., both as Chair of the Audit Committee, bringing valuable corporate governance experience to Cencora. This appointment coincides with the retirement of current CFO James F. Cleary, who will remain in an advisory capacity through the end of 2026. The company also reaffirmed its fiscal year 2026 adjusted diluted earnings per share guidance of $17.70 to $17.90, along with long-term guidance for adjusted operating income growth of 7% to 10% and adjusted diluted earnings per share growth of 10% to 14%. This filing provides details on Ms. Boratto's compensation package, including a substantial sign-on bonus and restricted stock units, as well as reaffirmation of financial outlook, signaling stability and continued strategic focus.
Cencora, Inc. 8-K Report, Financial Results (May 6, 2026)
Cencora, Inc. (COR) filed an 8-K on May 6, 2026, to report its financial results for the fiscal quarter ended March 31, 2026. The core of this filing is the attached news release, which contains the company's earnings announcement and will be discussed during an 8:30 a.m. Eastern time conference call and webcast on the same day. Investors can access the news release, presentation slides, and webcast link on Cencora's investor relations website. This filing is furnished and not deemed 'filed' under Section 18 of the Exchange Act, meaning it doesn't carry the same liabilities, but it's crucial for understanding the company's recent performance and outlook.
Cencora, Inc. 8-K Report, Regulation FD Disclosure (Mar 23, 2026)
Cencora, Inc. (COR) announced on March 23, 2026, that it has entered into a definitive agreement to acquire EyeSouth Partners' retina business. This strategic move signals Cencora's intent to expand its operations within a specialized segment of the healthcare market. While the financial terms and specific strategic benefits are not detailed in this 8-K filing, the acquisition is presented as a significant development. Investors should monitor future filings and press releases for more information on the transaction's financial impact, integration plans, and expected synergies. The filing also includes a standard cautionary note regarding forward-looking statements, highlighting potential risks and uncertainties associated with the transaction's completion and future performance.
Cencora, Inc. 8-K Report, Executive Changes (Mar 17, 2026)
Cencora, Inc. (COR) announced via an 8-K filing on March 17, 2026, that James F. Cleary will retire as Executive Vice President and Chief Financial Officer (CFO) effective June 30, 2026. This is a significant leadership transition, and importantly, the company stated that Mr. Cleary's retirement is not due to any disagreement regarding the Company's operations, policies, or practices, which suggests a planned and amicable departure. Investors should note that this announcement was made alongside a reaffirmation of Cencora's previously issued adjusted diluted earnings per share (EPS) guidance range for fiscal year 2026. The reaffirmation of guidance is a key takeaway, indicating that despite the upcoming CFO transition, management remains confident in their near-term financial outlook. While the immediate market reaction might focus on the CFO change, the consistent guidance suggests operational stability and that succession planning is likely underway or well-managed. Investors will want to monitor the company's communication regarding the appointment of a successor CFO and any potential impact on future financial strategies or reporting.
View all 8-K filings →